Personalized treatment based on a patient’s individual brain anatomyMore specific targeting for brain therapiesIncreased safetyDecreased complications associated with neurosurgical treatments
[更多]
Reduces chronic conditions assocated with menopause with an improved safety profile
[更多]
Intravenous administration of daunorubicin is an FDA-approved drug for the treatment of oncologic malignanciesDaunorubicin induces cell death and suppresses pulmonary artery constriction in a hypoxia-induced animal model of pulmonary hypertensionDaunorubicin mediated suppression of pulmonary artery .....
[更多]
| |<首頁 <-上一頁 下一頁-> 末頁>| |
